• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UnitedHealthcare to eliminate out-of-pocket costs on insulin, other prescription drugs

July 15, 2022 By Sean Whooley

Unitedhealthcare logoUnitedHealthcare announced today that it will eliminate out-of-pocket costs in standard fully insured group plans for certain prescription drugs.

Insulin, among a number of drugs used to treat emergencies including severe allergic reactions, hypoglycemia, opioid overdoses, and acute asthma attacks will be included in the new standard offering.

Along with insulin, epinephrine (for severe allergic reactions), glucagon (for hypoglycemia), Naloxone (for opioid overdoses) and albuterol (for acute asthma attacks) will be included with a $0 cost share.

UnitedHealthcare said in a news release that it will make the offering of preferred prescription drugs available to group fully insured plans potentially as early as Jan. 1, 2023, subject to any required regulatory approval.

Eliminating out-of-pocket expenses for such medications can help reduce the burden of medical costs on consumers and encourage better medication adherence, UnitedHealthcare said. This step represents part of its ongoing efforts to make healthcare more affordable, allowing people to get the drugs they need.

Offering preferred drugs at $0 cost share builds upon previous efforts by UnitedHealthcare and Optum Rx, including point-of-sale discounts that have offered millions of dollars in savings directly to consumers at the pharmacy counter.

“High prices are a significant barrier to prescription drugs for many people, so we are using our unique capabilities to deliver savings for consumers,” UnitedHealthcare CEO Brian Thompson said in the release. “We are doing what we can to shield people from the prices set by pharmaceutical companies, and hope all stakeholders also will act to make prescription drugs more affordable.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: insulin, UnitedHealthcare

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS